• Skip to primary navigation
  • Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Case reports
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • BC Issues until 2024
  • Submission
  • Istruction for authors
  • Search

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2014; 38(3) 198-202

Published on-line:

DOI:

Download in PDF:
Authentication required

Proteomica e metabolomica nello studio della malattia di Alzheimer

AUTHORS

Francesca Sicilia, Giulia Maria Sancesario, Giorgio Federici
Dipartimento di Medicina di Laboratorio, Fondazione Policlinico Tor Vergata, e Dipartimento di Medicina Sperimentale e Chirurgia, Università di Roma Tor Vergata, Roma

ABSTRACT

Proteomic and metabolomic approaches in the study of Alzheimer disease (AD)

Pathophysiologic changes associated with AD begin decades before the appearance of clinical symptoms; it is therefore essential an advancement of the knownledge of the etiopathogenetic process in early stages of disease. Proteomics and metabolomics are powerfull tools for the study and the comprehensive analysis of proteins and low MW compounds in a biological sample. These tools show great potential for the discovery of new biomarkers. Here we analyze recent developments in the application of proteomic and metabolomic technologies for searching new biomarkers for AD.

REFERENCES